Evidence map›Paper›PMID 40697457›Full record

ArticleRSC advances2025

LC-MS/MS-guided separation of guaiacolane-type sesquiterpenes with anti-inflammatory activities from

Xinyue Li, Yanfen Cai, Yunshuang Hu, Limei Miu, Yanyu Zhang, Shiyun Huang, Min Wei, Qing Ma, Zhongqiu Liu, Hua Zhou and 1 more

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinyue LiGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.ORCID https://orcid.org/0009-0003-7299-952X
Yanfen CaiGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.
Yunshuang HuGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.
Limei MiuGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.
Yanyu ZhangHenan Key Laboratory of Traditional Chinese Medicine Prescription and Syndrome Signaling & Henan International Joint Laboratory of Traditional Chinese Medicine Prescription and Syndrome Signaling, Henan University of Chinese Medicine Zhengzhou 450046 P. R. China.
Shiyun HuangGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.
Min WeiChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd Shenzhen 518110 P. R. China.
Qing MaChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd Shenzhen 518110 P. R. China.
Zhongqiu LiuGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.
Hua ZhouChinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin 519000 P. R. China gutcmzhs@hotmail.com.
Peng WuGuangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine Guangzhou 510006 P. R. China wupeng@gzucm.edu.cn +86-20-39358071 +86-20-39358651.ORCID https://orcid.org/0000-0003-1358-874X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four previously undescribed compounds, including three guaiacane-type sesquiterpenoids (1-3) and one oleanane-type triterpenoid (4), along with seven known sesquiterpenoids, were isolated from the aerial parts of

Identifiers

PMID40697457
PMCPMC12282369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.